



VIRTUAL MEETING & LISTENING SESSION – APRIL 27, 2022; 12-3 PM ET

USG Oversight Framework for Research Involving Enhanced Potential Pandemic Pathogens (ePPPs)

DRAFT AGENDA (weblink)

12:00-12:15 PM	<p>WELCOME & OVERVIEW <i>Lyric Jorgenson, PhD, Acting Associate Director for Science Policy, NIH</i></p>
12:15-1:45 PM	<p>SESSION 1: USG OVERSIGHT FRAMEWORK FOR RESEARCH INVOLVING ePPPs – SCOPE & IMPLEMENTATION <i>Moderator: Andrew Hebbeler, PhD, Assistant Director for Health and Life Sciences, White House Office of Science and Technology Policy</i></p> <p>Key Questions</p> <ul style="list-style-type: none"> • What are the strengths and weaknesses of the current USG ePPP oversight framework? • Does the scope of the USG ePPP oversight framework appropriately encompass potential risk while advancing life sciences research? • Are there opportunities to strengthen the implementation of the USG ePPP oversight framework? • What, if any, additional measures should be considered regarding US support of ePPP research internationally? <p>Speakers</p> <ul style="list-style-type: none"> • <i>Kanta Subbarao, MBBS, MPH, Director, WHO Collaborating Centre for Reference and Research on Influenza</i> • <i>Matthew Frieman, PhD, Associate Professor of Microbiology and Immunology, University of Maryland</i> • <i>Stefano Bertuzzi, PhD, MPH, CEO American Society for Microbiology</i> • <i>Felicia Goodrum Sterling, PhD, President, American Society for Virology</i> • <i>Thomas Inglesby, MD, Director, Johns Hopkins Center for Health Security, Bloomberg School of Public Health</i> • <i>Rocco Casagrande, PhD, Managing Director, Gryphon Scientific</i> <p>Public Comments (REGISTER HERE TO PROVIDE COMMENT!)</p>
1:45-1:55 PM	BREAK



<p>1:55-2:55 PM</p>	<p>SESSION 2: BALANCING SECURITY & TRANSPARENCY IN ePPP RESEARCH <i>Moderator: Cari Young, ScM, Acting Director of the Division of Biosafety, Biosecurity, and Emerging Technology Policy, Office of Science Policy, NIH</i></p> <p>Key Questions</p> <ul style="list-style-type: none">• What factors should be assessed/integrated into any ePPP oversight framework to appropriately prioritize public transparency while mitigating potential security risks?• Are there opportunities to strengthen the implementation of the USG ePPP oversight framework to optimize this balance?• Should there be limits to what information is shared about research involving ePPP?• How can the research community promote open and honest communication about research involving ePPP? <p>Speakers</p> <ul style="list-style-type: none">• <i>Gigi Kwik Gronvall, PhD, Senior Scholar, Johns Hopkins Center for Health Security, Associate Professor, Johns Hopkins School of Public Health</i>• <i>Megan Palmer, PhD, Executive Director, Bio Policy & Leadership Initiatives, Department of Bioengineering, Stanford University</i>• <i>Craig Reed, PhD, Frederick Maryland, Containment Laboratory Community Advisory Committee Member</i>• <i>Rebecca Moritz, MS, CBSP Biosafety Director and Responsible Official, Colorado State University</i>• <i>Gregory D. Koblenz, PhD, Assistant Professor and Director of Biodefense Graduate Programs, Schar School of Policy and Government, George Mason University</i> <p>Public Comments (REGISTER HERE TO PROVIDE COMMENT!)</p>
<p>2:55-3:00 PM</p>	<p>CLOSING REMARKS & ADJOURNMENT <i>Lyric Jorgenson, PhD, Acting Associate Director for Science Policy, NIH</i></p>